Wound-healing potential of human umbilical cord blood-derived mesenchymal stromal cells in vitro-a pilot study

Hijin You, Sik Namgoong, Seung-Kyu Han, Seong-Ho Jeong, Eun-Sang Dhong, Woo-Kyung Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background aims: Our previous studies demonstrated that human bone marrow-derived mesenchymal stromal cells have great potential for wound healing. However, it is difficult to clinically utilize cultured stem cells. Recently, human umbilical cord blood-derived mesenchymal stromal cells (hUCB-MSCs) have been commercialized for cartilage repair as a first cell therapy product that uses allogeneic stem cells. Should hUCB-MSCs have a superior effect on wound healing as compared with fibroblasts, which are the main cell source in current cell therapy products for wound healing, they may possibly replace fibroblasts. The purpose of this in vitro study was to compare the wound-healing activity of hUCB-MSCs with that of fibroblasts. Methods: This study was particularly designed to compare the effect of hUCB-MSCs on diabetic wound healing with those of allogeneic and autologous fibroblasts. Healthy (n = 5) and diabetic (n = 5) fibroblasts were used as the representatives of allogeneic and autologous fibroblasts for diabetic patients in the control group. Human UCB-MSCs (n = 5) were used in the experimental group. Cell proliferation, collagen synthesis and growth factor (basic fibroblast growth factor, vascular endothelial growth factor and transforming growth factor-β) production were compared among the three cell groups. Results: Human UCB-MSCs produced significantly higher amounts of vascular endothelial growth factor and basic fibroblast growth factor when compared with both fibroblast groups. Human UCB-MSCs were superior to diabetic fibroblasts but not to healthy fibroblasts in collagen synthesis. There were no significant differences in cell proliferation and transforming growth factor-β production. Conclusions: Human UCB-MSCs may have greater capacity for diabetic wound healing than allogeneic or autologous fibroblasts, especially in angiogenesis.

Original languageEnglish
Pages (from-to)1506-1513
Number of pages8
JournalCytotherapy
Volume17
Issue number11
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Mesenchymal Stromal Cells
Fetal Blood
Wound Healing
Fibroblasts
Transforming Growth Factors
Fibroblast Growth Factor 2
Cell- and Tissue-Based Therapy
Vascular Endothelial Growth Factor A
Collagen
Stem Cells
Cell Proliferation
In Vitro Techniques
Human Activities
Cartilage
Cultured Cells
Intercellular Signaling Peptides and Proteins
Bone Marrow
Control Groups

Keywords

  • Fibroblast
  • Human umbilical cord blood stem cells
  • Wound healing

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Cite this

Wound-healing potential of human umbilical cord blood-derived mesenchymal stromal cells in vitro-a pilot study. / You, Hijin; Namgoong, Sik; Han, Seung-Kyu; Jeong, Seong-Ho; Dhong, Eun-Sang; Kim, Woo-Kyung.

In: Cytotherapy, Vol. 17, No. 11, 01.11.2015, p. 1506-1513.

Research output: Contribution to journalArticle

@article{4b7509cbaf6e4b36a9ffcc680512bbd7,
title = "Wound-healing potential of human umbilical cord blood-derived mesenchymal stromal cells in vitro-a pilot study",
abstract = "Background aims: Our previous studies demonstrated that human bone marrow-derived mesenchymal stromal cells have great potential for wound healing. However, it is difficult to clinically utilize cultured stem cells. Recently, human umbilical cord blood-derived mesenchymal stromal cells (hUCB-MSCs) have been commercialized for cartilage repair as a first cell therapy product that uses allogeneic stem cells. Should hUCB-MSCs have a superior effect on wound healing as compared with fibroblasts, which are the main cell source in current cell therapy products for wound healing, they may possibly replace fibroblasts. The purpose of this in vitro study was to compare the wound-healing activity of hUCB-MSCs with that of fibroblasts. Methods: This study was particularly designed to compare the effect of hUCB-MSCs on diabetic wound healing with those of allogeneic and autologous fibroblasts. Healthy (n = 5) and diabetic (n = 5) fibroblasts were used as the representatives of allogeneic and autologous fibroblasts for diabetic patients in the control group. Human UCB-MSCs (n = 5) were used in the experimental group. Cell proliferation, collagen synthesis and growth factor (basic fibroblast growth factor, vascular endothelial growth factor and transforming growth factor-β) production were compared among the three cell groups. Results: Human UCB-MSCs produced significantly higher amounts of vascular endothelial growth factor and basic fibroblast growth factor when compared with both fibroblast groups. Human UCB-MSCs were superior to diabetic fibroblasts but not to healthy fibroblasts in collagen synthesis. There were no significant differences in cell proliferation and transforming growth factor-β production. Conclusions: Human UCB-MSCs may have greater capacity for diabetic wound healing than allogeneic or autologous fibroblasts, especially in angiogenesis.",
keywords = "Fibroblast, Human umbilical cord blood stem cells, Wound healing",
author = "Hijin You and Sik Namgoong and Seung-Kyu Han and Seong-Ho Jeong and Eun-Sang Dhong and Woo-Kyung Kim",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.jcyt.2015.06.011",
language = "English",
volume = "17",
pages = "1506--1513",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Wound-healing potential of human umbilical cord blood-derived mesenchymal stromal cells in vitro-a pilot study

AU - You, Hijin

AU - Namgoong, Sik

AU - Han, Seung-Kyu

AU - Jeong, Seong-Ho

AU - Dhong, Eun-Sang

AU - Kim, Woo-Kyung

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background aims: Our previous studies demonstrated that human bone marrow-derived mesenchymal stromal cells have great potential for wound healing. However, it is difficult to clinically utilize cultured stem cells. Recently, human umbilical cord blood-derived mesenchymal stromal cells (hUCB-MSCs) have been commercialized for cartilage repair as a first cell therapy product that uses allogeneic stem cells. Should hUCB-MSCs have a superior effect on wound healing as compared with fibroblasts, which are the main cell source in current cell therapy products for wound healing, they may possibly replace fibroblasts. The purpose of this in vitro study was to compare the wound-healing activity of hUCB-MSCs with that of fibroblasts. Methods: This study was particularly designed to compare the effect of hUCB-MSCs on diabetic wound healing with those of allogeneic and autologous fibroblasts. Healthy (n = 5) and diabetic (n = 5) fibroblasts were used as the representatives of allogeneic and autologous fibroblasts for diabetic patients in the control group. Human UCB-MSCs (n = 5) were used in the experimental group. Cell proliferation, collagen synthesis and growth factor (basic fibroblast growth factor, vascular endothelial growth factor and transforming growth factor-β) production were compared among the three cell groups. Results: Human UCB-MSCs produced significantly higher amounts of vascular endothelial growth factor and basic fibroblast growth factor when compared with both fibroblast groups. Human UCB-MSCs were superior to diabetic fibroblasts but not to healthy fibroblasts in collagen synthesis. There were no significant differences in cell proliferation and transforming growth factor-β production. Conclusions: Human UCB-MSCs may have greater capacity for diabetic wound healing than allogeneic or autologous fibroblasts, especially in angiogenesis.

AB - Background aims: Our previous studies demonstrated that human bone marrow-derived mesenchymal stromal cells have great potential for wound healing. However, it is difficult to clinically utilize cultured stem cells. Recently, human umbilical cord blood-derived mesenchymal stromal cells (hUCB-MSCs) have been commercialized for cartilage repair as a first cell therapy product that uses allogeneic stem cells. Should hUCB-MSCs have a superior effect on wound healing as compared with fibroblasts, which are the main cell source in current cell therapy products for wound healing, they may possibly replace fibroblasts. The purpose of this in vitro study was to compare the wound-healing activity of hUCB-MSCs with that of fibroblasts. Methods: This study was particularly designed to compare the effect of hUCB-MSCs on diabetic wound healing with those of allogeneic and autologous fibroblasts. Healthy (n = 5) and diabetic (n = 5) fibroblasts were used as the representatives of allogeneic and autologous fibroblasts for diabetic patients in the control group. Human UCB-MSCs (n = 5) were used in the experimental group. Cell proliferation, collagen synthesis and growth factor (basic fibroblast growth factor, vascular endothelial growth factor and transforming growth factor-β) production were compared among the three cell groups. Results: Human UCB-MSCs produced significantly higher amounts of vascular endothelial growth factor and basic fibroblast growth factor when compared with both fibroblast groups. Human UCB-MSCs were superior to diabetic fibroblasts but not to healthy fibroblasts in collagen synthesis. There were no significant differences in cell proliferation and transforming growth factor-β production. Conclusions: Human UCB-MSCs may have greater capacity for diabetic wound healing than allogeneic or autologous fibroblasts, especially in angiogenesis.

KW - Fibroblast

KW - Human umbilical cord blood stem cells

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84942550246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942550246&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2015.06.011

DO - 10.1016/j.jcyt.2015.06.011

M3 - Article

VL - 17

SP - 1506

EP - 1513

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 11

ER -